[HTML] nih.gov

Survival outcomes associated with clinical and pathological response following neoadjuvant FOLFIRINOX or gemcitabine/nab-paclitaxel chemotherapy in resected …

FI Macedo, E Ryon, SK Maithel, RM Lee… - Annals of …, 2019 - journals.lww.com
Objective: To compare the survival outcomes associated with clinical and pathological
response in pancreatic ductal adenocarcinoma (PDAC) patients receiving neoadjuvant …
被引用次数：136 相关文章 所有 7 个版本
[PDF] academia.edu

FOLFIRINOX versus gemcitabine/nab-paclitaxel for neoadjuvant treatment of resectable and borderline resectable pancreatic head adenocarcinoma

M Dhir, MS Zenati, A Hamad, AD Singhi… - Annals of surgical …, 2018 - Springer
Background Both FOLFIRINOX and gemcitabine/nab-paclitaxel (G-nP) are used
increasingly in the neoadjuvant treatment (NAT) of pancreatic ductal adenocarcinoma …
被引用次数：107 相关文章 所有 8 个版本
[HTML] nih.gov

Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer

CR Ferrone, G Marchegiani, TS Hong, DP Ryan… - Annals of …, 2015 - journals.lww.com
Purpose: On the basis of the ACCORD trial, FOLFIRINOX is effective in metastatic pancreatic
adenocarcinoma (PDAC), making it a rational choice for locally advanced PDAC (LA). Aims …
被引用次数：867 相关文章 所有 13 个版本
[PDF] jamanetwork.com

Evaluation of adjuvant chemotherapy in patients with resected pancreatic cancer after neoadjuvant FOLFIRINOX treatment

S van Roessel, E van Veldhuisen… - JAMA …, 2020 - jamanetwork.com
Importance The benefit of adjuvant chemotherapy after resection of pancreatic cancer
following neoadjuvant combination treatment with folinic acid, fluorouracil, irinotecan, and …
被引用次数：116 相关文章 所有 15 个版本
[HTML] nih.govFull View

Neoadjuvant FOLFIRINOX for borderline resectable pancreas cancer: a new treatment paradigm?

KK Christians, S Tsai, A Mahmoud, P Ritch… - The …, 2014 - academic.oup.com
Background. Borderline resectable pancreatic cancer is best treated by multimodality
therapy. FOLFIRINOX (5-fluorouracil, oxaliplatin, irinotecan, and leucovorin) tripled the …
被引用次数：212 相关文章 所有 13 个版本
[HTML] lww.com

[HTML][HTML] Factors predicting response, perioperative outcomes, and survival following total neoadjuvant therapy for borderline/locally advanced pancreatic cancer

MJ Truty, ML Kendrick, DM Nagorney, RL Smoot… - Annals of …, 2021 - journals.lww.com
Objective: To identify predictive factors associated with operative morbidity, mortality, and
survival outcomes in patients with borderline resectable (BR) or locally advanced (LA) …
被引用次数：356 相关文章 所有 12 个版本
[PDF] springer.com

A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma

PJ Hosein, J Macintyre, C Kawamura, JC Maldonado… - BMC cancer, 2012 - Springer
Abstract Background 5-fluorouracil, leucovorin, irinotecan and oxaliplatin (FOLFIRINOX) is
superior to gemcitabine in patients with metastatic pancreatic cancer who have a good …
被引用次数：262 相关文章 所有 22 个版本
[HTML] nih.gov

Surgical outcome results from SWOG S1505: a randomized clinical trial of mFOLFIRINOX versus gemcitabine/nab-paclitaxel for perioperative treatment of resectable …

SA Ahmad, M Duong, DPS Sohal, NS Gandhi… - Annals of …, 2020 - journals.lww.com
Objective: The optimal neoadjuvant therapy for resectable pancreatic ductal
adenocarcinoma (PDA) and the impact on surgical outcomes remains unclear. Methods …
被引用次数：179 相关文章 所有 9 个版本

Predictors of resectability and survival in patients with borderline and locally advanced pancreatic cancer who underwent neoadjuvant treatment with FOLFIRINOX

T Michelakos, I Pergolini… - Annals of …, 2019 - journals.lww.com
Objective: The aim of this study was to determine (1) whether preoperative factors can
predict resectability of borderline resectable (BR) and locally advanced (LA) pancreatic …
被引用次数：317 相关文章 所有 6 个版本
[HTML] nih.gov

Neoadjuvant modified (m) FOLFIRINOX for locally advanced unresectable (LAPC) and borderline resectable (BRPC) adenocarcinoma of the pancreas

M Blazer, C Wu, RM Goldberg, G Phillips… - Annals of surgical …, 2015 - Springer
Background For patients with metastatic pancreatic cancer, FOLFIRINOX (fluorouracil [5-FU],
leucovorin [LV], irinotecan [IRI], and oxaliplatin) has shown improved survival rates …
被引用次数：262 相关文章 所有 12 个版本